Filing summary: Owens & Minor, Inc. 10-Q, quarter ended March 31, 2015
Entity discrepancy: The request identifies ACCENDRA HEALTH INC, but the supplied filing is for Owens & Minor, Inc. This summary reflects the filing provided and does not establish that it belongs to the requested company.
Business context and reporting period
Owens & Minor distributes medical and surgical supplies and provides healthcare logistics services. It reports Domestic and International segments. This unaudited filing covers the first quarter of 2015 and compares results with the quarter ended March 31, 2014.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Net revenue | $2.391 billion | $2.256 billion |
| Gross margin | $297.6 million; 12.45% of revenue | $281.2 million; 12.46% |
| Operating earnings, GAAP | $41.0 million | $46.3 million |
| Net income | $18.9 million | $25.5 million |
| Diluted EPS | $0.30 | $0.41 |
| Operating cash flow | $168.7 million | $93.2 million |
| Cash and cash equivalents, quarter end | $159.1 million | $182.4 million |
Adjusted operating earnings, adjusted net income, and adjusted diluted EPS were $50.9 million, $27.5 million, and $0.44, respectively, versus $49.5 million, $27.7 million, and $0.44 a year earlier. These are non-GAAP measures that exclude acquisition-related and exit and realignment charges.
At March 31, 2015, total assets were $2.700 billion and total liabilities were $1.731 billion. Long-term debt, excluding current portion, was $574.6 million, compared with $608.6 million at year-end 2014. The company had $159.1 million in cash and no revolver borrowings; $445 million remained available under its $450 million facility, after letters of credit. Current assets were $1.864 billion and current liabilities $1.030 billion. The filing reports a quarterly dividend of $0.2525 per share.
Material changes versus the prior comparable period
- Revenue rose 6.0%. Domestic revenue increased 6.4%; International revenue declined 1.8% as unfavorable foreign exchange offset organic growth.
- GAAP operating earnings fell 11.5% and net income fell 25.7%. The prior-year quarter included a $5.3 million benefit from a direct-purchaser antitrust settlement that did not recur.
- Adjusted EPS was unchanged at $0.44. Domestic segment operating earnings declined $2.2 million; International improved from a $3.2 million operating loss to $0.4 million of operating income.
- Operating cash flow increased, primarily reflecting working-capital timing, including payments to vendors. Cash used in financing was $50.4 million, including $33.7 million of revolver repayment and $15.9 million of dividends.
- Quarter-end accumulated other comprehensive loss widened to $51.6 million from $24.0 million at year-end, primarily due to $27.9 million of currency translation losses.
Outlook, commentary, risks, and unusual items
- Medical Action and ArcRoyal, acquired in the fourth quarter of 2014 for combined consideration of $261.6 million net of cash acquired, contributed to the business mix and growth. Purchase price allocation remained preliminary; $150.6 million was preliminarily allocated to goodwill.
- Management expected approximately $7.0 million of additional exit and realignment charges during the remainder of 2015 for activities initiated through March 31. Q1 included $9.9 million of combined acquisition-related and exit and realignment charges, including $3.0 million of accelerated amortization for an information system being replaced.
- No specific revenue or earnings guidance was provided. Management said available operating cash and borrowing capacity were expected to fund working capital, capital spending, strategic growth, debt and lease payments, dividends, and other needs. Future dividends remain subject to board discretion and business conditions.
- Management cited pricing and competitive pressure, customer concentration and retention, supplier dependence, acquisition integration, healthcare regulation, international and currency exposure, fuel costs, financing access, information-system and data-security risks, and litigation and tax contingencies.
- The company settled a UK customer dispute and ended the service contract in Q1, paying approximately $3.9 million previously accrued; substantially all related year-end receivables had been collected. Management reported compliance with debt covenants and effective disclosure controls, while excluding the acquired businesses from its internal-control evaluation during the permitted first year after acquisition.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q names Owens & Minor, Inc., not ACCENDRA HEALTH INC.
- Review whether revenue growth and margins were affected by the fourth-quarter acquisitions and the change in accounting presentation for packaging costs.
- Assess the recurring versus nonrecurring effects of acquisition, integration, and restructuring charges, and the expected remaining 2015 charges.
- Monitor working-capital timing, cash conversion, foreign-exchange effects, and the sustainability of the improved International segment result.
- Check subsequent filings for acquisition purchase-price allocation, debt and covenant developments, and any change in dividend or repurchase plans.